CureVac announced a collaboration with myNEO last month to look for neoantigens on the surface of tumor cells in order to develop mRNA-based cancer vaccines.
Moderna and BioNTech, and CureVac, are known as the "mRNA Troika". However, the Phase 3 clinical trial of the mRNA COVID-19 vaccine developed by CureVac failed.
CureVac has fallen far behind Moderna and BioNTech due to the failure of the...
0 Commentarios
0 Acciones
1060 Views
0 Vista previa
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek